Form 4: Lexaria Bioscience Corp. Director Albert L. Reese Jr. Reports Acquisition of Stock Options
SEC Form 4
Director Albert L. Reese Jr. reports acquiring 11,000 stock options in Lexaria Bioscience Corp.
Summary
- On May 15, 2025, Albert L. Reese Jr., a director of Lexaria Bioscience Corp., reported acquiring 11,000 stock options.
- These options have an exercise price of $1.04 and expire on May 15, 2030.
- The acquisition increases Reese's direct holdings to 43,000 stock options.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing a director's acquisition of stock options, which is neutral in sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions and provides insight into the compensation structure and equity ownership of Lexaria Bioscience's directors.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/01/2021 | Date exercisable for stock options with an expiration date of 02/01/2026 and an exercise price of $3.00 |
| 03/08/2022 | Date exercisable for stock options with an expiration date of 03/08/2027 and an exercise price of $3.39 |
| 10/12/2022 | Date exercisable for stock options with an expiration date of 10/12/2027 and an exercise price of $1.96 |
| 07/25/2023 | Date exercisable for stock options with an expiration date of 07/25/2028 and an exercise price of $0.87 |
| 04/26/2024 | Date exercisable for stock options with an expiration date of 04/26/2029 and an exercise price of $2.36 |
| 07/26/2024 | Date exercisable for stock options with an expiration date of 07/26/2029 and an exercise price of $3.39 |
| 05/15/2025 | Date of transaction: Albert L. Reese Jr. acquired 11,000 stock options with an exercise price of $1.04 and an expiration date of 05/15/2030 |
| 05/15/2030 | Expiration date for the 11,000 stock options acquired on 05/15/2025 |
Keywords
stock options, director, form 4, beneficial ownership, Lexaria Bioscience Corp., LEXX, Albert L. Reese Jr.
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.